表紙
市場調査レポート

Myungmoon pharmaceutical Co.,Ltd.:製品パイプライン分析

Myungmoon pharmaceutical Co.,Ltd. - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 318578
出版日 ページ情報 英文 19 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.75円で換算しております。
Back to Top
Myungmoon pharmaceutical Co.,Ltd.:製品パイプライン分析 Myungmoon pharmaceutical Co.,Ltd. - Product Pipeline Review - 2015
出版日: 2015年08月12日 ページ情報: 英文 19 Pages
概要

Myungmoon pharmaceutical Co.,Ltd.は韓国に本社をおく製薬企業で、OTC/ETC製品の製造、卸売り、輸出入を行っており、取扱い製品は麻酔薬、消化器系、中枢神経系、抗骨関節炎薬、抗てんかん薬など多岐にわたります。

当レポートでは、Myungmoon pharmaceutical Co.,Ltd.における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

目次

Myungmoon pharmaceutical Co.,Ltd.の基本情報

  • Myungmoon pharmaceutical Co.,Ltd.の概要
  • 主要情報
  • 企業情報

Myungmoon pharmaceutical Co.,Ltd.:R&Dの概要

  • 主な治療範囲

Myungmoon pharmaceutical Co.,Ltd.:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

Myungmoon pharmaceutical Co.,Ltd.:パイプライン製品の概況

  • 初期段階にあるパイプライン製品
    • 創薬中の製品/併用療法モダリティ

Myungmoon pharmaceutical Co.,Ltd.:薬剤プロファイル

  • MM-A01-01
  • MM-P01-01
  • MM-P01-02
  • MM-P02-01

Myungmoon pharmaceutical Co.,Ltd.:パイプライン分析

  • 標的別
  • 分子タイプ別
  • 作用機序別

Myungmoon pharmaceutical Co.,Ltd.:本社と子会社の所在地

  • 本社
  • 支社および子会社

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07494CDB

Summary

Global Markets Direct's, 'Myungmoon pharmaceutical Co.,Ltd. - Product Pipeline Review - 2015', provides an overview of the Myungmoon pharmaceutical Co.,Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Myungmoon pharmaceutical Co.,Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Myungmoon pharmaceutical Co.,Ltd. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Myungmoon pharmaceutical Co.,Ltd.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Myungmoon pharmaceutical Co.,Ltd.'s pipeline products

Reasons to buy

  • Evaluate Myungmoon pharmaceutical Co.,Ltd.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Myungmoon pharmaceutical Co.,Ltd. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Myungmoon pharmaceutical Co.,Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Myungmoon pharmaceutical Co.,Ltd. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Myungmoon pharmaceutical Co.,Ltd.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Myungmoon pharmaceutical Co.,Ltd. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Myungmoon pharmaceutical Co.,Ltd. Snapshot
    • Myungmoon pharmaceutical Co.,Ltd. Overview
    • Key Information
    • Key Facts
  • Myungmoon pharmaceutical Co.,Ltd. - Research and Development Overview
    • Key Therapeutic Areas
  • Myungmoon pharmaceutical Co.,Ltd. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Myungmoon pharmaceutical Co.,Ltd. - Pipeline Products Glance
    • Myungmoon pharmaceutical Co.,Ltd. - Early Stage Pipeline Products
      • Discovery Products/Combination Treatment Modalities
  • Myungmoon pharmaceutical Co.,Ltd. - Drug Profiles
    • MMA-0101
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MMP-0101
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MMP-0102
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MMP-0201
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Myungmoon pharmaceutical Co.,Ltd. - Pipeline Analysis
  • Myungmoon pharmaceutical Co.,Ltd. - Pipeline Products by Target
  • Myungmoon pharmaceutical Co.,Ltd. - Pipeline Products by Molecule Type
  • Myungmoon pharmaceutical Co.,Ltd. - Pipeline Products by Mechanism of Action
  • Myungmoon pharmaceutical Co.,Ltd. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Myungmoon pharmaceutical Co.,Ltd., Key Information
  • Myungmoon pharmaceutical Co.,Ltd., Key Facts
  • Myungmoon pharmaceutical Co.,Ltd. - Pipeline by Indication, 2015
  • Myungmoon pharmaceutical Co.,Ltd. - Pipeline by Stage of Development, 2015
  • Myungmoon pharmaceutical Co.,Ltd. - Monotherapy Products in Pipeline, 2015
  • Myungmoon pharmaceutical Co.,Ltd. - Discovery, 2015
  • Myungmoon pharmaceutical Co.,Ltd. - Pipeline by Target, 2015
  • Myungmoon pharmaceutical Co.,Ltd. - Pipeline by Molecule Type, 2015
  • Myungmoon pharmaceutical Co.,Ltd. - Pipeline Products by Mechanism of Action, 2015
  • Myungmoon pharmaceutical Co.,Ltd., Other Locations

List of Figures

  • Myungmoon pharmaceutical Co.,Ltd. - Pipeline by Top 10 Indication, 2015
Back to Top